Cancer Screening in the UK 2026
Cancer screening in the United Kingdom is one of the NHS’s most consequential public health responsibilities — and in 2026, it sits at the intersection of genuine progress and serious systemic strain. The UK operates four established national cancer screening programmes: breast, cervical, bowel, and the rapidly expanding lung cancer screening programme launched nationally in 2023. Together, these programmes invite tens of millions of people annually, identify cancers before symptoms develop, and save thousands of lives each year. According to Cancer Research UK, an estimated 90,000 cancer cases were caught by UK screening programmes over the five years between 2019 and 2024 — including approximately 62,600 breast cancers detected through mammography alone. The NHS Long Term Plan sets a target for 75% of cancers to be diagnosed at stage 1 or 2 by 2028, a goal that is directly dependent on screening uptake recovering and improving across all four programmes. The challenge in 2026 is that the NHS is simultaneously managing a post-pandemic recovery in screening coverage, a record volume of urgent cancer referrals, and a set of cancer waiting time standards it has not met in nearly a decade.
The context for UK cancer screening statistics in 2026 is defined by three converging pressures that stretch across the entire cancer pathway from invitation to treatment. First, screening uptake, while recovering in breast and bowel programmes, remains below pre-pandemic levels in some cohorts and has been in long-term decline for cervical cancer since 2013–14. Second, cancer waiting times are under extreme stress: the 62-day standard — that patients should begin treatment within two months of an urgent referral — has not been met since December 2015, and the 28-day Faster Diagnosis Standard is being met but is still below its interim improvement target in some months. Third, the volume of people coming forward with suspected cancer is at record highs — over 281,000 Faster Diagnosis Standard referrals per month on average in 2025–26 — straining diagnostic services that are simultaneously trying to absorb the backlog from the COVID-19 years. Against that backdrop, the new Lung Cancer Screening Programme is the most significant structural expansion of NHS cancer screening in a generation, and its early results — 7,193 lung cancers diagnosed, 63.1% at stage 1 — represent one of the most important early detection success stories in modern NHS history.
Interesting Facts About UK Cancer Screening in 2026
UK CANCER SCREENING FAST FACTS — 2026
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
~90,000 cancers caught by screening (5 years, 2019–2024) ████████████████████ Cancer Research UK
62,600 breast cancers detected (same 5-year period) ████████████████████ Cancer Research UK
Breast screening coverage: 71.8% (2024/25) ████████████████████ NHS England IPR March 2026
Bowel screening uptake: 72.9% (2024/25) ████████████████████ NHS England IPR March 2026
Cervical screening coverage: 68.8% (England, 2023/24) ████████████████████ NHS Digital / CRUK
62-day cancer standard last met: December 2015 ████████████████████ Cancer Research UK May 2026
62-day performance March 2026: 72.8% (target: 85%) ████████████████████ NHS England May 2026
Lung cancer screening: 7,193 cancers in 5 years ████████████████████ Nature Medicine March 2026
63.1% of lung screen cancers found at stage 1 ████████████████████ Nature Medicine March 2026
51–55% of all UK cancers currently diagnosed early ████████████████████ Cancer Research UK report
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Interesting Fact | Detail / Data | Source |
|---|---|---|
| ~90,000 cancers caught by UK screening (2019–2024) | Estimated 90,000 cancer cases identified through breast, cervical, and bowel screening programmes over five years | Cancer Research UK, December 2024 |
| 62,600 breast cancers detected in five years | Breast screening alone diagnosed approximately 62,600 cancer cases between 2019 and 2024 | Cancer Research UK, December 2024 |
| Breast screening coverage: 71.8% (2024/25) | Rose 1.8 percentage points from 2023/24 — continued post-pandemic recovery; published March 2026 | NHS England Integrated Performance Report, March 2026 |
| Bowel screening uptake: 72.9% (2024/25) | Increased from 71.8% in 2023/24 — multi-year positive momentum continuing | NHS England Integrated Performance Report, March 2026 |
| Cervical screening coverage: 68.8% (2023/24) | A slight increase from 68.7% the prior year — but down from 74.2% in 2013/14, a decade of decline | NHS Digital; CRUK |
| 62-day cancer waiting target last met: December 2015 | The standard that 85% of patients should begin treatment within 62 days of urgent referral has not been achieved for over a decade | Cancer Research UK May 15, 2026 |
| 62-day performance March 2026: 72.8% | Average for full year April 2025–March 2026: 69.4% — improved from 68.5% for April 2024–March 2025 | NHS England Cancer Waiting Times, May 14, 2026 |
| 281,470 average monthly FDS referrals (2025/26) | The average number of Faster Diagnosis Standard referrals per month — the highest volume ever recorded | NHS England Cancer Waiting Times Statistical Release May 2026 |
| 51–55% of UK cancers diagnosed early (stage 1 or 2) | The proportion has shown little change despite screening investment — well below the NHS 75% by 2028 target | Cancer Research UK “Cancer in the UK” report |
| 7,193 lung cancers diagnosed through LCSP (to March 2025) | Over five years of the NHS Lung Cancer Screening Programme — 63.1% at stage 1, 12.6% at stage 2 | Nature Medicine, March 23, 2026 (Lee et al.) |
| 2.5 million lung health check invitations sent (2019–2025) | The NHS invited over 2.5 million people — 1.2 million (49%) underwent a lung health check | Nature Medicine March 2026; Cancer Therapy Advisor April 2026 |
| Cervical cancer rates fell ~24% in the UK | Due to high HPV vaccination uptake and screening — a notable success within an otherwise declining programme | Ezra.com / NHS; Cancer Research UK |
Source: Cancer Research UK “Cancer in the UK” overview report; NHS England Integrated Performance Report March 24, 2026; NHS England Cancer Waiting Times Statistical Release (March 2026, published May 14, 2026); Nature Medicine Vol. 32, pp. 1817–1826 (March 23, 2026) — Lee et al.; Cancer Research UK news December 2024; Cancer Research UK “Cancer Waiting Times” update May 15, 2026; Nuffield Trust cancer screening tracker; NHS Digital cervical screening annual report 2023/24
The headline achievement — 90,000 cancers caught by UK screening between 2019 and 2024 — represents lives measurably extended or saved by NHS programmes that for all their operational difficulties still function as a critical gateway to early diagnosis. Breast screening’s 71.8% coverage in 2024/25 marks meaningful recovery from the pandemic nadir, and the bowel programme’s 72.9% uptake reflects the positive impact of the shift to home-based FIT testing, which removed the requirement for clinic appointments and significantly improved participation. But the systemic story of UK cancer screening in 2026 is one of stubborn structural gaps: 51–55% of all UK cancers are still diagnosed at stage 1 or 2 — a proportion that has barely moved despite years of investment, expanded screening programmes, and public awareness campaigns. The NHS Long Term Plan target of 75% early diagnosis by 2028 is not currently on track by any metric, and the combination of below-target screening uptake and the worst cancer waiting times performance in over a decade makes the path to that target unclear.
The 62-day standard’s absence from NHS performance tables for more than ten years is the single most important benchmark context for understanding UK cancer care in 2026. When the standard was set at 85% — meaning 85% of patients should begin cancer treatment within two months of an urgent GP referral — it was considered achievable and clinically reasonable. The fact that it was last met in December 2015 and has drifted to 72.8% in March 2026 is not primarily a function of declining NHS ambition; it is a function of demand growth outpacing diagnostic and treatment capacity. The 281,470 average monthly Faster Diagnosis Standard referrals recorded in 2025–26 — the highest volume ever — is a sign of better GP awareness and lower referral thresholds, which is clinically positive, but it places unprecedented pressure on a radiology, pathology, and oncology workforce that was already stretched before the pandemic.
UK Breast & Cervical Cancer Screening Rates in 2026 | Coverage, Targets & Trends
BREAST & CERVICAL SCREENING COVERAGE — UK 2026
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
BREAST SCREENING (England)
2018/19 (pre-pandemic) 71.1% ████████████████████
2022/23 (post-pandemic low) 64.6% ████████████████████
2023/24 70.0% ████████████████████
2024/25 (latest) 71.8% ████████████████████ (+1.8pp yr-on-yr)
CERVICAL SCREENING (England)
2013/14 (peak) 74.2% ████████████████████
2022/23 68.7% ████████████████████
2023/24 (latest) 68.8% ████████████████████ (slight recovery)
5.12M invited / 3.25M tested (5.3% drop in participation 2023/24)
UK cervical coverage range: ~55%–69% across UK nations
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Screening Metric | Latest Data | Trend | Source |
|---|---|---|---|
| Breast screening coverage — England (2024/25) | 71.8% | +1.8 percentage points vs 2023/24; recovering post-pandemic but still below some pre-COVID levels | NHS England IPR, March 2026 |
| Breast screening coverage — England (2022/23 low) | 64.6% — worst post-pandemic figure | Down from 71.1% in 2018/19 — a 6.5 percentage point pandemic-related drop | Cancer Research UK December 2024 |
| Cervical screening coverage — England (2023/24) | 68.8% — slight uptick | Down from 74.2% in 2013/14 — 5.4 percentage point decline over a decade | NHS Digital annual report; CRUK |
| Cervical screening invitations vs uptake (2023/24) | 5.12 million invited; only 3.25 million tested — a 5.3% fall in participation vs prior year | North Tyneside JSNA analysis / NHS Digital 2023/24 | |
| UK-wide cervical coverage range | Between ~55% and 69% across the four UK nations | England higher than some devolved nations; Scotland, Wales, NI vary significantly | Cancer Research UK “Cancer in the UK” report |
| NHS breast screening age range | Women aged 50–70 invited every 3 years | Expanding with timed invitations reintroduced from April 2025 | NHS England; Nuffield Trust |
| First NHS breast screening awareness campaign | First-ever national NHS campaign to highlight breast screening benefits, launched February 2025 (with Breast Cancer Now) | — | Nuffield Trust; NHS England |
| NHS cervical screening age range | Women aged 25–64 invited every 3 years (25–49) and 5 years (50–64) | Uses HPV primary screening since December 2019 — more sensitive than prior cytology | NHS; Nuffield Trust |
| HPV primary screening sensitivity | HPV testing is more sensitive than cytology — identifies more women at risk of cervical cancer | Led to more follow-up referrals and some temporary capacity strain | Nuffield Trust; CRUK |
| NHS app cervical screening bookings | NHS England enabling cervical screening bookings via NHS app — targeting breast screening bookings by app by 2026 | — | Cancer Research UK December 2024 |
| Key barrier: no symptoms = don’t attend | Survey data confirms: most common reason for non-attendance at bowel and breast screening is “I don’t have symptoms so I don’t think it’s for me” | — | Cancer Research UK December 2024 |
| NHS 75% early diagnosis target by 2028 | NHS aims to diagnose 75% of cancers at stage 1 or 2 by 2028 — currently not on track | — | Cancer Research UK; NHS Long Term Plan |
Source: NHS England Integrated Performance Report March 24, 2026; Cancer Research UK December 2024; NHS Digital Cervical Screening Annual Report 2023/24; North Tyneside JSNA Cervical Cancer Screening analysis 2025; Nuffield Trust cancer screening resource; NHS England Long Term Plan
The breast screening recovery to 71.8% in 2024/25 is a genuine and encouraging milestone, achieved through a combination of targeted access interventions, the publication of updated screening guides in 30 languages and British Sign Language, and the reintroduction of timed appointment invitations for all women from April 2025. These are evidence-based improvements that address the structural barriers — linguistic, logistical, and informational — that have historically driven differential uptake among ethnic minority women and those in lower socioeconomic groups. NHS England has also published a dedicated strategy, Tackling the Uptake Challenge, setting out its progress and plans — a document that reflects a recognition that improving coverage in the communities with the lowest current uptake requires more than a leaflet.
The cervical screening picture is more troubling. Despite a marginal 0.1 percentage point improvement in 2023/24 coverage, the programme is a decade into a long-term decline that has taken England from a 74.2% coverage rate in 2013/14 to 68.8% today — a trajectory that, unless reversed, places the NHS’s ambition to eliminate cervical cancer in England by 2040 (aligned with the WHO target of fewer than 4 cases per 100,000 women) in serious jeopardy. The move to HPV primary screening in 2019 improved sensitivity but introduced a new challenge: more women being referred for follow-up colposcopy at a time when colposcopy capacity is already stretched. The NHS home testing kit trial across 166 primary care centres in areas with low attendance is the most promising structural intervention for restoring cervical screening coverage — early data suggests home HPV testing can reach under-screened populations at far higher rates than clinic-based invitations — but it remains a trial rather than a national rollout as of 2026.
UK Bowel Cancer & Lung Cancer Screening in 2026 | Programmes, Results & Expansion
BOWEL & LUNG CANCER SCREENING — UK 2026
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
BOWEL CANCER SCREENING (England)
Uptake 2023/24: 71.8% ████████████████████
Uptake 2024/25: 72.9% ████████████████████ (+1.1pp)
Age range: 54–74 (expanding to 50+)
Expansion launch: January 2025 (kits to age 50+)
UK-wide range: 66%–70% across UK nations
LUNG CANCER SCREENING (England)
Cancers diagnosed (to March 2025): 7,193 ████████████████████
Diagnosed at stage 1: 63.1% ████████████████████
Compared to outside screening: <30% at stage 1/2
People invited (2019–2025): 2.5M+ ████████████████████
Coverage target by 2025 (40%): 36% as of Feb 2025
Full UK coverage target: March 2030
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Screening Metric | Latest Data | Key Detail | Source |
|---|---|---|---|
| Bowel screening uptake — England (2024/25) | 72.9% | Up from 71.8% in 2023/24 — continuing multi-year positive momentum | NHS England IPR, March 2026 |
| UK-wide bowel screening uptake range | 66%–70% across UK nations | FIT (faecal immunochemical test) home testing has been the primary driver of uptake improvement | Cancer Research UK “Cancer in the UK” report |
| Bowel screening age expansion (England) | Expanded to those aged 50 and above — kits began rolling out in January 2025 | Previously available from age 54; expansion follows NICE guidance and international evidence | Nuffield Trust; NHS England |
| FIT as key driver of uptake | Shift from FOBT to FIT home testing dramatically improved participation — no clinic appointment needed | — | Cancer Research UK “Cancer in the UK” report |
| Estimated 1 million missed bowel invitations (pandemic) | An estimated 1 million bowel cancer screening invitations were not sent in England due to COVID-19 | Despite this, 2020/21 rates increased due to home-test compatibility with pandemic conditions | Nuffield Trust |
| Lung cancer screening eligibility | People aged 55–74 who are current or former smokers assessed via multivariable risk models | Eligible individuals receive low-dose CT (LDCT) of the thorax | Nature Medicine March 2026; NHS England |
| Total invited to lung health check (2019–2025) | More than 2.5 million people invited; 1.2 million (49%) underwent a lung health check | Around 90% of those referred for LDCT underwent it | Nature Medicine March 2026; Cancer Therapy Advisor April 2026 |
| Total lung cancers diagnosed (to March 2025) | 7,193 lung cancers — 63.1% at stage 1 and 12.6% at stage 2 — 75.7% caught at early stage | Compared to less than 30% diagnosed at stage 1 or 2 outside screening | Nature Medicine March 23, 2026; WYHAT Cancer Alliance |
| Early-stage detection vs. non-screening | Inside LCSP: 75%+ at stage 1/2; outside LCSP: less than 30% at stage 1/2 | A transformative difference in outcomes — treating stage 1 lung cancer offers dramatically better survival | WY&H Cancer Alliance; Roy Castle Foundation |
| UK coverage target (Phase 1) | 40% of eligible population by March 2025 | Actual coverage: 36% as of February 2025 — slightly behind pace | Roy Castle Foundation August 2025 |
| UK coverage full rollout target | 100% by March 2030 | Wales announced rollout following successful pilot in June 2025; first Welsh invitations expected 2027 | Cancer Research UK LCSP page |
| Funding concern flagged | FY2025/26 lung screening funding agreed at a lower level than original rollout plan — multiple lung cancer organisations raised alarm | Roy Castle Foundation August 2025 |
Source: NHS England Integrated Performance Report March 24, 2026; Nature Medicine Vol. 32, 1817–1826 (March 23, 2026) — Lee et al.; Cancer Therapy Advisor April 8, 2026; Cancer Research UK Lung Cancer Screening page; Roy Castle Foundation Briefing on Lung Cancer Screening August 2025; Nuffield Trust cancer screening resource; WY&H Cancer Alliance; CRUK “Cancer in the UK” report
The UK Lung Cancer Screening Programme’s five-year outcomes data, published in Nature Medicine on March 23, 2026, represent the most significant positive contribution to cancer screening policy published in the UK this year. 7,193 lung cancers diagnosed across more than 2.5 million invitations, with 63.1% at stage 1 and 12.6% at stage 2, means the programme is finding three in four lung cancers while they are still treatable with curative intent — a dramatic contrast with the fewer than 30% stage 1/2 rate seen in lung cancer diagnosed outside the screening programme. Lung cancer’s notorious late-stage diagnosis profile — which historically made it the UK’s biggest cancer killer — is being directly and measurably altered in the populations the screening programme has reached. The paper’s finding that the programme has already “increased the early-stage proportion of lung cancer in England over five years, particularly in socioeconomically deprived regions” is the most important equity finding in UK cancer research in 2026.
The funding concern raised by the Roy Castle Foundation, British Thoracic Oncology Group, and eight other lung cancer organisations in their August 2025 joint briefing cannot be overlooked. If FY2025/26 funding for the lung screening programme was agreed at a level below the original rollout plan — and if funding beyond that year remains uncertain — the programme risks falling further behind its 40% coverage target and potentially reversing the inequality reductions already achieved. Every month of delay in reaching high-risk populations in underserved areas is a delay in catching lung cancers at stage 1 rather than stage 4. The organisations’ call for inclusion of lung screening in the National Cancer Plan (2025) with fully funded rollout commitments to March 2030 reflects a justified urgency: programmes that pause or slow mid-rollout do not simply pause their benefits — they lose the compounding gains of earlier detection in populations that have already waited longest.
UK Cancer Waiting Times & Diagnostic Backlog in 2026 | NHS Performance Data
UK CANCER WAITING TIMES PERFORMANCE — MARCH 2026
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
28-day FDS (target 80%): 79.4% March 2026 (below target)
31-day treatment (target 96%): 92.8% March 2026 (below target)
62-day standard (target 85%): 72.8% March 2026 (12.2pp below target)
62-day annual avg 2025/26: 69.4% (up from 68.5% prior year)
62-day last met: December 2015 — 10+ years ago
Monthly FDS referrals avg: 281,470/month (record high 2025/26)
Record referrals in March: 259,000+ (up from 258,828 in February)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Waiting Time Metric | March 2026 Performance | Target | Last Met | Source |
|---|---|---|---|---|
| Faster Diagnosis Standard (FDS) — 28-day | 79.4% diagnosed or cancer ruled out within 28 days of urgent referral | 80% (interim target) | — | Cancer Research UK May 15, 2026; NHS England May 14, 2026 |
| 31-day treatment standard | 92.8% received first cancer treatment within 31 days of decision to treat | 96% | — | BMA NHS Backlog Data Analysis; Cancer Research UK |
| 62-day combined standard | 72.8% in March 2026 — patients treated within 62 days of urgent referral | 85% | December 2015 — over 10 years ago | Cancer Research UK May 15, 2026; NHS England |
| 62-day annual average (2025/26) | 69.4% (April 2025–March 2026) | 85% | — | NHS England Cancer Waiting Times Statistical Release May 14, 2026 |
| 62-day annual average (2024/25) | 68.5% (April 2024–March 2025) | 85% | — | NHS England Cancer Waiting Times Statistical Release |
| Average monthly FDS referrals (2025/26) | 281,470 per month — all-time record volume | — | “More people are being referred for suspected cancer than ever before” | NHS England May 2026; Cancer Research UK “Cancer in the UK” report |
| FDS referrals — March 2026 | 259,000+ (up from 258,828 in February 2026) | — | — | NHS England Cancer Waiting Times Statistical Release May 2026 |
| 28-day FDS interim target | NHS England 2025/26 planning guidance set 80% as interim target by March 2026 | 80% | 79.4% in March — just below | BMA NHS Backlog Data Analysis |
| Bowel cancer incidence in young adults | Bowel cancer incidence in England rose 52% since the early 1990s among younger people — one of the steepest globally | — | Ezra.com / NHS England data 2024–25 | |
| Cervical cancer elimination target | NHS England reaffirmed November 2023: eliminate cervical cancer in England by 2040, aligned with WHO target of <4 cases per 100,000 women | — | North Tyneside JSNA 2025; NHS England |
Source: NHS England Cancer Waiting Times Statistical Release (March 2026, published May 14, 2026); Cancer Research UK “Cancer Waiting Times: Latest Updates and Analysis” (May 15, 2026); BMA NHS Backlog Data Analysis (updated May 2026); House of Commons Library NHS Key Statistics: England (updated June 2026); Cancer Research UK “Cancer in the UK” overview report
The UK cancer waiting times data for 2026 tells a story of a system doing more than it has ever done — and still falling short. The 281,470 average monthly Faster Diagnosis Standard referrals in 2025/26 reflects a genuine and important shift in clinical practice: GPs are referring more people earlier, thresholds have been lowered, awareness has improved, and the public are presenting sooner. These are exactly the behaviours that cancer survival improvement requires. But the infrastructure receiving those referrals — the endoscopy services, radiology departments, histopathology labs, and oncology units — has not expanded proportionally. The result is a system in which more people are entering the cancer pathway than at any point in history while the proportion completing that pathway within clinically recommended timeframes is at multi-decade lows.
The 62-day standard’s ten-year gap from the target is not simply a performance statistic. It represents tens of thousands of individual patients per year whose cancers progress — sometimes from stage 1 to stage 2, sometimes from stage 2 to stage 3 — during delays that clinical evidence consistently links to worse outcomes. The House of Commons Library’s June 2026 briefing notes that NHS staff numbers have increased substantially — doctors up 24% and nurses up 22% over five years to February 2026 — confirming that the problem is not a failure to recruit; it is a failure of capacity expansion to keep pace with demand growth, systemic inefficiency in patient flow, and the structural legacy of a diagnostic estate that needs significant capital investment to deliver on the volume of referrals the clinical workforce is now generating. Until the gap between finding and treating cancers closes, the 90,000 lives touched by UK screening in the last five years will continue to be partially offset by preventable delays in the pathway from screening-detected cancer to curative treatment.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
